05.18.26 -- Kodak's CEO Leans Into Biopharma Manufacturing – "I'm An Operator"

Strategic location, strong regulatory oversight, institutional stability, and deep expertise reduce risk, speed approvals, and enable reliable, long-term pharmaceutical development partnerships.

A global partner delivering end‑to‑end drug development, manufacturing, and packaging with deep expertise, advanced facilities, and support across key modalities.

GLP‑1 therapies are changing injectable care and driving rapid progress in delivery and manufacturing. See how patient needs, emerging tech, and regulations are reshaping chronic treatment.

Strategic tech transfer and scalable manufacturing enabled rapid NDA approval, delivering registration batches and accelerating commercialization of a novel therapy for drug-resistant infections.

To keep pace with surging GLP-1 demand, pharma needs partners that can rapidly scale injectable production while maintaining flexibility, quality, and regulatory rigor.

Discover how surging demand for GLP-1 and other therapeutics is transforming fill/finish capacity and regulatory standards. Learn how CDMOs are adapting to the complex needs of emerging modalities.

Our disposable pen is a proven, globally adopted drug delivery platform with over 175 million units sold, supporting diverse therapies in 40+ countries.

Explore how our capabilities in phage and yeast surface display can drive your next protein engineering or therapeutic antibody development project forward.

A sponsor’s commitment to rigorous impurity control throughout manufacturing is vital to ensuring continuous patient safety. E&Ls, nitrosamines, and PFAS are among the most critical impurities to test.

For biopharmas looking to outsource their early phase development, consider working with a CDMO partner that has the knowledge and experience to navigate microbial fermentation.

Gain insights into a “simul-spray” process pioneering for combining small and large molecules into a single, atomized drug product for inhalation administration.

Operational excellence in drug manufacturing comes from predictability. Standardized, consistent processes reduce volatility and ensure steady, high‑quality progress.

Accelerate your path to IND and FiH with AI-driven design, advanced cell line engineering, and intensified processes delivering high titers in 9–14 months.

Managing chemical migration from packaging and process equipment is essential to protect patient safety, maintain drug stability, and ensure regulatory compliance.

Integrated biocatalysis and continuous processing are reshaping therapeutic manufacturing, enabling faster scale‑up, greater efficiency, and lower costs as peptides and oligonucleotides meet demands.